StreetInsider.com News Articles

Form 144 Eton Pharmaceuticals, Filed by: Gruber James R.

Tue, 23 Jun 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260623/26679985.html

Form 144 Eton Pharmaceuticals, Filed by: Gruber James R.

Tue, 23 Jun 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260623/26679985.html

Form 4 Eton Pharmaceuticals, For: Jun 17 Filed by: Adams Jennifer McKie

Wed, 17 Jun 2026 17:08:00 -0400

si-local-file:///var/storage/secattach/20260617/26660887.html

Form 4 Eton Pharmaceuticals, For: Jun 17 Filed by: Adams Jennifer McKie

Wed, 17 Jun 2026 17:08:00 -0400

si-local-file:///var/storage/secattach/20260617/26660887.html

Form 144 Eton Pharmaceuticals, Filed by: Adams Jennifer McKie

Wed, 17 Jun 2026 11:44:00 -0400

si-local-file:///var/storage/secattach/20260617/26658591.html

Form 144 Eton Pharmaceuticals, Filed by: Adams Jennifer McKie

Wed, 17 Jun 2026 11:44:00 -0400

si-local-file:///var/storage/secattach/20260617/26658591.html

Form 8-K Eton Pharmaceuticals, For: Jun 09

Tue, 09 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260609/26624183.html

Form 8-K Eton Pharmaceuticals, For: Jun 09

Tue, 09 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260609/26624183.html

Form 144 Eton Pharmaceuticals, Filed by: Gruber James R.

Tue, 02 Jun 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260602/26592660.html

Form 144 Eton Pharmaceuticals, Filed by: Gruber James R.

Tue, 02 Jun 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260602/26592660.html

Form 3 Eton Pharmaceuticals, For: Jun 01 Filed by: Matthews Judith M.

Mon, 01 Jun 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260601/26584118.html

Form 3 Eton Pharmaceuticals, For: Jun 01 Filed by: Matthews Judith M.

Mon, 01 Jun 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260601/26584118.html

Form 4 Eton Pharmaceuticals, For: May 28 Filed by: BRYNJELSEN SEAN

Fri, 29 May 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260529/26575430.html

Form 4 Eton Pharmaceuticals, For: May 28 Filed by: BRYNJELSEN SEAN

Fri, 29 May 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260529/26575430.html

Form 144 Eton Pharmaceuticals, Filed by: BRYNJELSEN SEAN

Thu, 28 May 2026 15:12:00 -0400

si-local-file:///var/storage/secattach/20260528/26565925.html

Form 144 Eton Pharmaceuticals, Filed by: BRYNJELSEN SEAN

Thu, 28 May 2026 15:12:00 -0400

si-local-file:///var/storage/secattach/20260528/26565925.html

Form 4 Eton Pharmaceuticals, For: May 22 Filed by: Krempa David

Wed, 27 May 2026 18:28:00 -0400

si-local-file:///var/storage/secattach/20260527/26559421.html

Form 4 Eton Pharmaceuticals, For: May 22 Filed by: Krempa David

Wed, 27 May 2026 18:28:00 -0400

si-local-file:///var/storage/secattach/20260527/26559421.html

Form 144 Eton Pharmaceuticals, Filed by: Krempa David

Fri, 22 May 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260522/26542097.html

Form 144 Eton Pharmaceuticals, Filed by: Krempa David

Fri, 22 May 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260522/26542097.html

H.C. Wainwright Reiterates Buy Rating on Eton Pharmaceuticals (ETON)

Thu, 21 May 2026 06:40:05 -0400

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $57.00 price target on Eton Pharmaceuticals (NASDAQ: ETON).

The analyst commented: "On May 18, 2026, Eton announced a supply and distribution agreement with an affiliate of Knight Therapeutics for exclusive U.S. commercialization rights to IMPAVIDO (oral miltefosine), the first and only FDA-approved drug for visceral, cutaneous, and mucosal leishmaniasis, a rare parasitic disease transmitted by the bite of infected sand flies. Rights to this drug are expected to become effective on September 26, 2026. Leishmaniasis is a rare, sand-fly-borne parasitic disease whose most severe form — visceral leishmaniasis — affects internal

Form 8-K Eton Pharmaceuticals, For: May 18

Tue, 19 May 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260519/26522112.html

Form 8-K Eton Pharmaceuticals, For: May 18

Tue, 19 May 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260519/26522112.html

Eton Pharmaceuticals acquires US rights to rare disease drug IMPAVIDO

Tue, 19 May 2026 16:30:13 -0400

Eton Pharmaceuticals Inc. (NASDAQ: ETON) announced it entered into a supply and distribution agreement to obtain exclusive U.S. commercialization rights for IMPAVIDO (miltefosine) from an affiliate of Knight Therapeutics Inc. The agreement takes effect September 26, 2026.

IMPAVIDO is an FDA-approved oral therapy for treating visceral, cutaneous, and mucosal leishmaniasis caused by specific Leishmania species in adults and adolescents over 12 years old weighing more than 30 kilograms. The drug has been commercially available in the United States since 2016.

Leishmaniasis is a parasitic disease transmitted through infected sand fly bites. The disease presents in multiple forms, including cutaneous leishmaniasis causing skin

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)

Tue, 19 May 2026 16:30:00 -0400

IMPAVIDO^® is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis caused by specific Leishmania species
Leishmaniasis is a rare but potentially life-threatening parasitic disease that can cause severe skin lesions or systemic infection involving internal organs
Exclusive U.S. commercialization rights to IMPAVIDO^® take effect September 26, 2026

DEER PARK, Ill., May 19, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced it has entered into a supply